علاج تصلب الأذن مع ضعف وظيفة الكلى

References

• The use of this therapy is contraindicated in patients with impaired renal function because excretion of sodium fluoride may be reduced with resulting toxic levels.
• Alendronate, a bisphosphonate similar in action to etidronate, is recommended in a daily dose of a 10-mg tablet; risedronate is recommended at a dose of 5 mg/d.
• Formulations with a higher concentration of alendronate and risedronate have been developed with a more convenient, once-a-week dosing of 70 and 35 mg, respectively.
• The bisphosphonates that present formulations for intravenous use are Clodronate, Pamidronate, and zoledronate at doses of 1500 mg (monthly), 90 mg (monthly), and 4 mg (annual), respectively, for infusion over 4 hours for both clodronate and pamidronate and over 15 minutes for zoledronate.
• The use of inhibitors of bone metabolism aims to preserve hearing thresholds (sensorineural component) and improve symptoms such as tinnitus and vertigo.